β-Escin sodium inhibits inducible nitric oxide synthase expression via downregulation of the JAK/STAT pathway in A549 cells

Molecular Carcinogenesis

Volumn 50, Issue 12, 2011, Pages 945-960

  Ji, Deng Bo ^a   Xu, Bo ^a   Liu, Jing Tao ^a   Ran, Fu Xiang ^a   Cui, Jing Rong ^a  

^a PEKING UNIVERSITY   (China)

Author keywords

Nitric oxide; Protein tyrosine kinase; Protein tyrosine phosphatase; SHP2; Signal transducer and transcription activator

Indexed keywords

BETA ESCIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; JANUS KINASE 2; MITOGEN ACTIVATED PROTEIN KINASE P38; PERVANADATE; PROTEIN TYROSINE PHOSPHATASE SHP 2; SMALL INTERFERING RNA; STAT1 PROTEIN; STAT3 PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; ENZYME INACTIVATION; ENZYME INHIBITION; GENE SILENCING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LUNG CARCINOMA; MITOCHONDRIAL MEMBRANE POTENTIAL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SARCOMA; SIGNAL TRANSDUCTION;

ACTIVE TRANSPORT, CELL NUCLEUS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; DOWN-REGULATION; ENZYME ACTIVATION; ENZYME INHIBITORS; ESCIN; HUMANS; JANUS KINASES; JNK MITOGEN-ACTIVATED PROTEIN KINASES; LUNG; LUNG NEOPLASMS; MAP KINASE SIGNALING SYSTEM; NF-KAPPA B; NITRIC OXIDE SYNTHASE TYPE II; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 11; RNA INTERFERENCE; RNA, SMALL INTERFERING; STAT TRANSCRIPTION FACTORS; VANADATES;

AESCULUS; AESCULUS HIPPOCASTANUM;

EID: 80255122688     PISSN: 08991987     EISSN: 10982744     Source Type: Journal    
DOI: 10.1002/mc.20762     Document Type: Article

References (36)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics. CA Cancer J Clin 2007; 57: 43-66.
2. Lin WW, Karin M. cytokine-mediated A between link innate immunity, inflammation, and cancer. J Clin Invest 2007; 117: 1175-1183.
3. Dijkstra G, Moshage H, van Dullemen HM, et al. Expression of nitric oxide synthase and formation of nitrotyrosine and reactive oxygen species in inflammatory bowel disease. J Pathol 1998; 186: 416-421.
4. Wilson KT, Fu S, Ramanujam KS, Meltzer SJ. Increased expression of inducible nitric oxide synthase and cyclooxygenase-2 in Barrett's esophagus and associated adenocarcinomas. Cancer Res 1998; 58: 2929-2934.
5. Singh RP, Agarwal R. Inducible nitric oxide synthase-vascular endothelial growth factor axis: A potential target to inhibit tumor angiogenesis by dietary agents. Curr Cancer Drug Targets 2007; 7: 475-483.
6. Kisley LR, Barrett BS, Bauer AK, et al. Genetic ablation of inducible nitric oxide synthase decreases mouse lung tumorigenesis. Cancer Res 2002; 62: 6850-6856.
7. Husain K. Exercise conditioning attenuates the hypertensive effects of nitric oxide synthase inhibitor in rat. Mol Cell Biochem 2002; 231: 129-137.
8. Tarsitano CA, Paffaro VA Jr, Pauli JR, et al. Hepatic morphological alterations, glycogen content and cytochrome P450 activities in rats treated chronically with Nω-nitro-L-arginine methyl ester (L-NAME). Cell Tissue Res 2007; 329: 45-58.
9. Sirtori CR. Aescin: Pharmacology, pharmacokinetics and therapeutic profile. Pharmacol Res 2001; 44: 183-193.
10. Patlolla JM, Raju J, Swamy MV, Rao CV. β-Escin inhibits colonic aberrant crypt foci formation in rats and regulates the cell cycle growth by inducing p21 (waf1/cip1) in colon cancer cells. Mol Cancer Ther 2006; 5: 459-466.
11. Wang T, Fu FH, Zhang LM, Han B, Zhu M, Zhang XM. Effects of escin on acute inflammation and the immune system in mice. Pharmacol Rep 2009; 61: 697-704.
12. Guo W, Xu B, Yang XW, Liu Q, Cui JR. The anticancer effect of β-escin sodium. Chin Pharmacol Bull 2003; 19: 351-352.
13. Wang XH, Xu B, Liu JT, Cui JR. Effect of β-escin sodium on endothelial cells proliferation, migration and apoptosis. Vasc Pharmacol 2008; 49: 158-165.
14. Imbert V, Rupec RA, Livolsi A, et al. Tyrosine phosphorylation of I kappa B-alpha activates NF-kappa B without proteolytic degradation of I kappa B-alpha. Cell 1996; 86: 787-798.
15. Chu SC, Marks-Konczalik J, Wu HP, Banks TC, Moss J. Analysis of the cytokine-stimulated human inducible nitric oxide synthase (iNOS) gene: Characterization of differences between human and mouse iNOS promoters. Biochem Biophy Res Commun 1998; 248: 871-878.
16. Zhang ZQ, Hu Y, Wang BJ, Zhao W, Lin ZX. Establishment and characterization of a spontaneously immortalized human lung epithelial cell line HLEC. Acta Anat Sin 2005; 36: 113-116.
17. Archer S. Measurement of nitric oxide in biological models. FASEB J 1993; 7: 349-360.
18. Schoene NW, Kamara KS. Population doubling time, phosphatase activity, and hydrogen peroxide generation in jurkat cells. Free Radic Biol Med 1999; 27: 364-369.
19. Towbin H, Staehlin T, Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: Procedure and some applications. Proc Natl Acad Sci USA 1979; 76: 4350.
20. Lechner M, Lirk P, Rieder J. Inducible nitric oxide synthase (iNOS) in tumor biology: The two sides of the same coin. Semin Cancer Biol 2005; 15: 277-289.
21. Lee JK, Choi SS, Won JS, Suh HW. The regulation of inducible nitric oxide synthase gene expression induced by lipopolysaccharide and tumor necrosis factor-α in C6 cells: Involvement of AP-1 and NF-κB. Life Sci 2003; 73: 595-609.
22. Lee TW, Chen GG, Xu H, et al. Differential expression of inducible nitric oxide synthase and peroxisome proliferator-activated receptor gamma in non-small cell lung carcinoma. Eur J Cancer 2003; 39: 1296-1301.
23. Jenkins DC, Chartes IG, Thomsen TT, et al. Role of nitric oxide in tumor growth. Proc Natl Acad Sci USA 1995; 92: 4392-4396.
24. Lala PK, Chakraborty C. Role of nitric oxide in carcinogenesis and tumour progression. Lancet Oncol 2001; 2: 149-156.
25. Kleinert H, Pautz A, Linker K, Schwarz PM. Regulation of the expression of inducible nitric oxide synthase. Eur J Pharmacol 2004; 500: 255-266.
26. Ganster RW, Taylor BS, Shao L, Geller DA. Complex regulation of human inducible nitric oxide synthase gene transcription by Stat 1 and NF-κB. Proc Natl Acad Sci USA 2001; 98: 8638-8643.
27. Xu W, Comhair SA, Zheng S, et al. STAT-1 and c-Fos interaction in nitric oxide synthase-2 gene activation. Am J Physiol Lung Cell Mol Physiol 2003; 285: L137-L148.
28. Chen Z, Han ZC. STA T3: A critical transcription activator in angiogenesis. Med Res Rev 2008; 28: 185-200.
29. Schultz J, Koczan D, Schmitz U, et al. Tumor-promoting role of signal transducer and activator of transcription (Stat)1 in late-stage melanoma growth. Clin Exp Metastasis 2010; 27: 133-140.
30. Kisseleva T, Bhattacharya S, Braunstein J, Schindler CW. Signaling through the JAK/STAT pathway, recent advances and future challenges. Gene 2002; 285: 1-24.
31. Chim CS, Fung TK, Cheung WC, Liang R, Kwong YL. SOCS1 and SHP1 hypermethylation in multiple myeloma: Implications for epigenetic activation of the Jak/STAT pathway. Blood 2004; 103: 4630-4635.
32. Baron M, Davignon JL. Inhibition of IFN-gamma-induced STAT1 tyrosine phosphorylation by human CMV is mediated by SHP2. J Immunol 2008; 181: 5530-5536.
33. Sun S, Steinberg BM. PTEN is a negative regulator of STAT3 activation in human papillomavirus-infected cells. J Gen Virol 2002; 83: 1651-1658.
34. Irie-Sasaki J, Sasaki T, Matsumoto W. CD45 is a JAK phosphatase and negatively regulates cytokine receptor signaling. Nature 2001; 409: 349-354.
35. Fechir M, Linker K, Pautz A, et al. Tristetraprolin regulates the expression of the human inducible nitric-oxide synthase gene. Mol Pharm 2005; 67: 2148-2161.
36. Ishikawa K, Takenaga K, Akimoto M, et al. ROS-generating mitochondrial DNA mutations can regulate tumor cell metastasis. Science 2008; 320: 661-664.